American Thoracic Society, European Respiratory Society (2002) American thoracic society/European respiretory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine, 165, 277-304. doi:10.1164/ajrccm.165.2.ats01
has been cited by the following article:
- TITLE: Stem cell therapy for idiopathic pulmonary fibrosis: How far are we from the bench to the bedside?
- AUTHORS: Zheng Wang, Xiaoju Zhang, Yi Kang, Yanli Zeng, Hongmei Liu, Xiaoqian Chen, Lijun Ma
- KEYWORDS: Pulmonary Fibrosis; Mesenchymal Stem Cells; Tissue Engineering; Embryonic Stem Cells; Alveolar Epithelial Cell
JOURNAL NAME: Journal of Biomedical Science and Engineering
Sep 05, 2014
- ABSTRACT: Idiopathic pulmonary fibrosis (IPF) is characterized by exuberant apoptosis and inadequate regeneration of lung parenchyma cells. Intratracheal alveolar type II epithelial cell instillation alleviates lung inflammation and fibrosis. Resident lung epithelial stem cells, as well as exogenous mesenchymal stem cells, are capable of differentiating into lung epithelial cells and repair the injured lung. It is thus supposed that, either engraftment of exogenous stem cells, or methods facilitating endogenous lung stem cell proliferation, are promising treatments for IPF, a devastating disease. Arrays of cellular and animal studies have shown the potential of stem cells in alleviating experimental lung fibrosis. Moreover, clinical trials have been launched to investigate the potentials of cell-based therapy in IPF patients. We intend to discuss the newest advances on stem cell therapy in pulmonary fibrosis, particularly the advantages, promises, and possible hurdles to pass from the successes in laboratory experiments to the eventual clinical applications.